Cocrystal Pharma, Inc.
Bothell, Washington, United States · Biotechnology, Healthcare, Health Care
Cocrystal (OTCQB:COCP) is a pharmaceutical company.
Key facts
- Headquarters
- Bothell, Washington, United States
- Employees
- 11
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (COCP)
- Website
- cocrystalpharma.com
Recent activity at Cocrystal Pharma, Inc.
- : Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer
- : SEC 8-K (7.01): On September 9, 2026, Cocrystal Pharma, Inc. announced through a press release that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139). This study evaluates the efficacy of CDI-988 as both a preventive and treatment option for norovirus infections. The completion of this dosing marks a significant milestone in the clinical development of the drug, which aims to address a significant public health challenge associated with norovirus. The press release is included as Exhibit 99.1 in the filing.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On August 17, 2026, Cocrystal Pharma, Inc. announced the appointment of Dr. Carol L. Brosgart to its Board of Directors. This strategic move is aimed at enhancing the company's governance and expertise within the board, which could influence future directions and decisions. The press release associated with this announcement indicates a commitment to bolstering the leadership team. The appointment reflects the company's ongoing efforts to strengthen its management framework and align with industry standards in leadership.
- : SEC 8-K (1.01): On July 31, 2026, Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with OPKO Health, Inc., whereby Cocrystal sold 5,474,053 shares of its common stock at a price of $0.9134 per share, yielding gross proceeds of $5.0 million. Dr. Phillip Frost, CEO of OPKO and co-founder of Cocrystal, is a significant figure in this transaction, highlighting an interconnected leadership. The proceeds are earmarked for advancing the company's clinical candidate programs and general corporate purposes. This transaction emphasizes Cocrystal's ongoing commitment to strengthening its financial footing for future developments.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On June 3, 2026, Cocrystal Pharma, Inc. appointed James Sapirstein as the new Chief Executive Officer. This significant leadership change was communicated through a press release, indicating the company's strategic move towards enhancing its executive management team. The announcement is expected to bring a fresh perspective to the company's direction and operations as they navigate the pharmaceutical landscape. The role shift underscores the company's commitment to growth and operational excellence in its future endeavors.
- : SEC 8-K (7.01): On May 26, 2026, Cocrystal Pharma, Inc. issued a press release discussing its novel direct-acting antivirals, highlighting recent advancements in its pharmaceutical development. This announcement is significant as it showcases the company's progress in antiviral therapies, which could have implications for their market position and ongoing research initiatives. The press release, attached as Exhibit 99.1, outlines the details of the novel products and their potential impact on public health, positioning Cocrystal Pharma as a key player in the antiviral space.
- : SEC 8-K (7.01): On April 30, 2026, Cocrystal Pharma, Inc. issued a press release regarding the presentation of their first oral protease inhibitor, CDI-988, at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. This disclosure highlights the mechanism of action and clinical advancement of CDI-988, showcasing the company's ongoing developments in antiviral research. The press release aims to inform shareholders and stakeholders of the significant progress in their drug development pipeline. The information provided in this item and the associated exhibit are not intended to be filed under the Securities Act or the Exchange Act.
- : SEC 8-K (7.01): On April 2, 2026, Cocrystal Pharma, Inc. announced via a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral, direct acting protease inhibitor, CDI-988. This designation is significant as CDI-988 represents the first oral antiviral candidate being developed for treating and preventing norovirus infection. The press release details the implications of this designation for the company's pipeline and provides context regarding the urgency and potential impact on public health related to norovirus infections. The information is reported in a manner that complies with Regulation FD requirements, ensuring it is accessible to the investment community.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Cocrystal Pharma, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2017 | Seed | $3.0M |
| Sep 2016 | Seed | $4.0M |
| Mar 2016 | Venture | $5.0M |
Leadership
- Gary Wilcox, Vice Chairman of the Board of Directors
- Raymond Schinazi, Director
- Steven Rubin, Director
- Jane Hsiao, Director
- Phillip Frost, Director
- David Block, Director
Verified email and direct lines for Cocrystal Pharma, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Cocrystal Pharma, Inc. in the news
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire (Apr 02, 2026)
- Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance Australia (Jun 14, 2017)
- Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results - GlobeNewswire (Nov 15, 2026)
Companies similar to Cocrystal Pharma, Inc.
- Yarrow Bioscience · Biotechnology, Healthcare, Health Care, Therapeutics
- Retension Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
- Aarvik Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Galectin · Biotechnology, Healthcare, Health Care, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Therapeutics
About Cocrystal Pharma, Inc.: questions and answers
What does Cocrystal Pharma, Inc. do?
Cocrystal (OTCQB:COCP) is a pharmaceutical company.
Where is Cocrystal Pharma, Inc. headquartered?
Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, United States.
How many employees does Cocrystal Pharma, Inc. have?
Cocrystal Pharma, Inc. has about 11 employees.
Has Cocrystal Pharma, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Cocrystal Pharma, Inc.. The most recent, Seed of $3.0M, was in May 2017.
What is the latest news on Cocrystal Pharma, Inc.?
On Jun 3, 2026, Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer
Is Cocrystal Pharma, Inc. a public company?
Yes. Cocrystal Pharma, Inc. is publicly traded under the ticker COCP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy